Caris Life Sciences’ scientific experts and external collaborators are contributing to major advances in the understanding of blood-based circulating microvesicles (cMV) and their potential utility to aid in the diagnosis, prognosis, and theranosis of cancer and other complex diseases. Posters and abstracts highlighting the promise of ADAPT Biotargeting System™ are listed below.

Comparison of progression-free survival (PFS) on comprehensive multiplatform profiling-guided therapy to PFS on prior therapy-

Comprehensive analysis of cancers of unknown primary for the biomarkers of response to immune checkpoint blockade therapy

High-Intermediate Risk Endometrial Cancer: Can Gene Expression Predict Recurrence?

Molecular Profiling for Clinical Decision Making in Advanced Cancer: A Clinical Appraisal

Mutational burden, immune checkpoint expression, and mismatch repair in glioma: implications for immune checkpoint immunotherapy

Identification of molecular targets in vulvar cancers

Comparative molecular profiling of HPV-induced squamous cell carcinomas

BRCA2, EGFR, and NTRK mutations in mismatch repair-deficient colorectal cancers with MSH2 or MLH1 mutations

Mismatch-repair deficiency predicts response of solid tumors to PD-1 blockade

RNASeq analysis of glioma tumors reveal targetable gene fusions